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Rationale: Pseudomonas aeruginosa (Pa) serology could potentially be a useful adjunct to respiratory culture methods for the detection of initial or
early Pa infection in patients with cystic ﬁbrosis (CF).
Objective: To evaluate the utility ofPa serology to predictPa isolation from respiratory (generally oropharyngeal) cultures in the subsequent 6 or 12 months
among young children with CF from whom Pa had never been previously cultured. Pa serology was also evaluated in a group of healthy controls.
Methods: Children ≤ 12 years of age without prior isolation of Pa from respiratory cultures participating in the Early Pseudomonal Infection
Control EPIC Observational Study (EPIC OBS) had annual serum samples for measurement of antibodies against alkaline protease, elastase and
exotoxin A using a commercial kit; controls had a single serum sample. Logistic regression with generalized estimating equations was used to
characterize associations between log10 serum antibody titers and ﬁrst isolation of Pa from a respiratory culture within the subsequent 6 or
12 months, with adjustment for sex and age. Receiver operating characteristic curves were used to optimize antibody titer cutpoints by age group.
The diagnostic properties of each antibody were estimated using these optimized cutpoints.
Results: Pa serology was evaluated in 582 children with CF (2084 serum samples) and 94 healthy controls. There was substantial overlap between
serum antibody titers among controls, CF patients who did not acquire Pa (N = 261) and CF patients who did acquire Pa (N = 321). The
maximum positive predictive value for ﬁrst Pa positive culture within the ensuing 6 months was 76.2% and maximum negative predictive value
was 72.1% for any antigen or combination of antigens; values were similar for 12 months.Abbreviations: CF, cystic fibrosis; Pa, Pseudomonas aeruginosa; OP, oropharyngeal; BAL, bronchoalveolar lavage; EPIC OBS, Early Pseudomonas Infection
Control Observational Study; CFFNPR, CFF National Patient Registry; GEE, generalized estimating equations; ROC, receiver operating characteristic; AUC, area
under the curve; CFTR, cystic fibrosis transmembrane regulator; PPV, positive predictive value; NPV, negative predictive value.
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Progressive obstructive lung disease due to chronic airway
infection and inflammation is the leading cause of morbidity and
mortality in cystic fibrosis (CF), with the bacterial pathogen
Pseudomonas aeruginosa (Pa) playing a prominent role [1].
Initial Pa acquisition generally occurs in early childhood [2,3],
but is often transient [2] and may be limited to the upper airways
[4]. In contrast, approximately 80% of CF adults has chronic
airway Pa infection [5], which is associated with more rapid
lung function decline [3,6], increased morbidity [3,7] and
decreased survival [8,9]. Today, children with CF are routinely
treated with antipseudomonal antibiotics upon first Pa isolation
in an attempt to eradicate the organism [10,11]. Eradication of
early Pa infection has a roughly 80% success rate [11–13] and
has been shown to reduce the prevalence of chronic Pa infection
in CF cohorts compared to historical controls [14–16].
The accurate detection of early Pa infection is problematic, as
young children and those with mild lung disease typically do not
expectorate sputum. Surveillance respiratory cultures in these
patients are typically performed on oropharyngeal (OP) swabs.
While OP cultures are known to have imperfect diagnostic
accuracy compared to lower airway cultures [4,17], they are
nonetheless standard of care in the U.S. andmany other countries,
and are widely used to guide treatment decisions [18], define
stages of Pa infection [19] and predict clinical outcomes [20,21].
Serum titers of antibodies against Pa antigens have been
shown to be elevated in chronic Pa infection [22,23] and to
distinguish intermittent from chronic Pa colonization [24,25].
However, as most chronically infected patients expectorate
sputum, the clinical utility of serology in this context is limited.
In contrast, it has been suggested that Pa serology could prove
a useful adjunct to respiratory culture methods for the detection
of initial or early Pa infection [24,26,27], as serology has the
potential advantages of being more accurate than upper airway
cultures and less resource-intensive and invasive than BAL.
The diagnostic accuracy of Pa serology relative to concurrent
respiratory cultures remains controversial [17,28–30].
Importantly, several studies have demonstrated that positive
Pa serology may precede initial isolation of Pa from both upper
[2,3,25,29,31] and lower [2] airway cultures. If positive Pa
serology could predict subsequent isolation ofPa from respiratory
cultures, eradication therapy could potentially be initiated at an
earlier stage to improve outcomes; this has been advocated [24]
but not yet investigated.
The Early Pseudomonas Infection Control Observational
Study (EPIC OBS) is a U.S. national prospective study to
evaluate the risk factors for and clinical outcomes associated
with isolation of Pa from respiratory cultures in a large cohort of
children with CF who were Pa-culture negative at enrollment[32]. The objective of the current analysis was to evaluate the
utility of Pa serology to predict subsequent Pa isolation from
respiratory (generally OP) culture among young children with
CF from whom Pa had never been previously cultured. We
hypothesized that Pa serology would have acceptable diagnos-
tic accuracy in predicting first isolation of Pa from respiratory
cultures within the ensuing 6 or 12 months. As part of the
current analysis, we also examined Pa serology and OP cultures
in a cohort of children without CF undergoing elective surgical
procedures at a single institution to assess the levels of anti-Pa
antibodies in the unaffected population. Portions of this work
have previously been published in abstract form.
2. Methods
2.1. Study participants and samples
The design of the EPIC OBS has been reported elsewhere
[33,34]. Children with an established diagnosis of CF
[35] ≤ 12 years of age were enrolled at 59 accredited U.S. CF
care centers between 2004 and 2006. Annual serum samples were
collected for serology and banking, and the results of clinical
respiratory cultures were recorded in the CFF National Patient
Registry (CFFNPR). Eligibility criteria for participation in the
current analysis were 1) no prior isolation of Pa from respiratory
cultures since CF diagnosis, confirmed with CFFNPR data, 2) no
loss to follow up or isolation of Pa from a respiratory culture in
the first 120 days after enrollment [36] (as these individuals may
have had had Pa infection prior to enrollment), and 3) at least one
serum sample collected. Written informed consent was obtained
from the family of each participant and the study was approved
by the Institutional Review Board at each participating site.
Serum samples collected through 2009 and data collected through
2010 were included in the current analysis.
2.2. Non-CF controls
Otherwise healthy children ≤ 18 years of age undergoing a
clinically indicated procedure that required sedation or anesthesia
at Seattle Children's Hospital, Seattle, WA, USA between
September 2008 and February 2010 were recruited. Exclusion
criteria included: (1) presence of indwelling catheters or devices
(including myringotomy tubes) at enrollment or within the past
year; (2) oral or IV antibiotic treatment within the past month;
(3) presence of congenital or acquired immunosuppression;
(4) history of cancer; (5) currently undergoing an otolaryngology
or dental procedure; (6) immediate family member with CF;
(7) blood transfusion within the past year. A serum sample for
serology and an OP swab for culture were collected from each
participant. The study was approved by the Seattle Children's
Table 1
Baseline characteristics of children with CF.
Did not acquire Pa
(N = 321)
Acquired Pa
(N = 261)
Total
(N = 582)
Age, years mean (SD) 5.0 (3.5) 5.5 (3.4) 4.8 (3.4)
Age distribution
0–3 years, n (%) 114 (35.5%) 106 (40.6%) 220 (37.8%)
N3–6 years, n (%) 84 (26.2%) 66 (25.3%) 150 (25.8%)
N6–12 years, n (%) 123 (38.3%) 89 (34.1%) 212 (36.4%)
Male, n (%) 157 (48.9%) 127 (48.7%) 284 (48.8%)
CFTR functional class a
High risk 210 (65.4%) 210 (85%) 420 (72.2%)
Low risk 53 (16.5%) 14 (5.4%) 67 (11.5%)
Not classified 51 (15.9%) 26 (10%) 77 (13.2%)
Missing 7 (2.2%) 11 (4.2%) 18 (3.1%)
Pancreatic sufficient b 73 (22.7%) 23 (8.8%) 96 (16.5%)
a High risk: both alleles with mutations in functional class 1, 2 or 3; low risk:
at least one allele with a class 4 or 5 mutation; not classified: functional class not
able to be determined based on mutations detected [46].
b Defined by pancreatic enzyme replacement therapy use in the CFF Registry.
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parents/guardians, as well as assent from participants as
applicable. The respiratory culture results from this cohort have
been previously published [34].
2.3. Pseudomonas serology
Serum samples were analyzed for titers of antibodies to the
Pa antigens alkaline protease, exotoxin A, and elastase by
Mediagnost® (Reutlingen, Germany) using their commercially
available IgG enzyme immunoassay system [24,28,37]. Assays
were batched and performed in duplicate. The lower limits of
quantification were 0.41, 0.15 and 0.35 titer/ml for alkaline
protease, exotoxin A and elastase, respectively (equal to 10 times
the standard deviation of the blank). Intraassay variances were
4.39, 5.3 and 11.5% of the coefficient of variation (CV) and
interassay variances were 5.7, 7.7 and 8.0% of the CV for alkaline
protease, elastase and exotoxin A, respectively. The linearity of
sample dilution has been proven for dilution range of 1:500 to
1:24,000 by the manufacturer. An independent evaluation of the
test system has been conducted [24,28].
2.4. Statistical analyses
Logistic regression models were used to characterize associ-
ations between log10 serum antibody titers and first isolation ofPa
from a respiratory culture within the subsequent 6 or 12 months,
with generalized estimating equations (GEE) methods used to
account for repeated observations per patient, and adjustment for
sex, age (1–≤3 years, N3–≤6 years, N6 years) and time (days)
between serum sample and respiratory culture. Receiver operating
characteristic (ROC) curves were used to optimize antibody titer
cutpoints to maximize the sensitivity and specificity of each
antibody and by age group (0–b6 years, ≥6 years), using the
area under the curve (AUC). The diagnostic properties of each
serologic assay, including sensitivity, specificity, positive predic-
tive value, and negative predictive value were estimated based on
these optimized cutpoints. Similar analyses were performed for
concurrent respiratory cultures (defined as collection within
3 weeks of the serum collection date) for comparison purposes.
Analyses were performed using R version 2.15.1 (R Foundation
for Statistical Computing, Vienna, Austria) and SAS, version 9.2
(SAS Institute Inc., Cary, NC).
3. Results
A total of 1797 children with CF were enrolled in EPIC OBS
between 2004 and 2006, of which 687 had no isolation of Pa from
respiratory cultures prior to or during the first 120 days after
enrollment. Of these 687 children, 582 had at least one serum
sample collected during the observation period and therefore
comprise the cohort for the current analyses. These 582 children
contributed 2084 serum samples; 261 children (44.8%) had a first
Pa-positive respiratory culture during the observation period and
321 remained Pa-negative. At baseline (Table 1), participants who
subsequently acquired Pa were similar to those who remained Pa
negative with respect to age and sex, but the proportion of childrenwith a high risk CFTR genotype was higher in participants who
acquired Pa (85.0% versus 65.4%, P b .0001), as was the
prevalence of pancreatic insufficiency (91.2% versus 77.3%,
P b .0001). A serum sample for serology and a simultaneous OP
swab for culture were collected from 94 non-CF controls, who had
a mean (SD) age of 8.5 (5.4) years; 54 were male. Pawas isolated
from only 1 of the 94 OP cultures.
3.1. Serum antibody titers and association with concurrent or
subsequent Pa isolation from respiratory cultures
Among the 261 children with CF who acquired Pa during
the observation period, 169 (64.8%) had serum samples
collected within 6 months prior to Pa isolation and all had a
serum sample within 12 months prior to Pa isolation. A total of
68 (26.1%) had serum samples collected concurrently with Pa
isolation, with a median elapsed time between the recorded date
of serum collection and respiratory sample collection of 0.0 day
(mean = 0.94 day, SD = 3.86 days) for this group.
Alkaline protease titers tended to be higher in CF patients than
in controls, though these titers did not distinguish between CF
patients who remained Pa negative and those who acquired Pa
(Fig. 1). Exotoxin A titers tended to be highest in CF patients who
were concurrently Pa positive. In general, however, there was
substantial overlap between titers of all three antigens across
participant groups (Fig. 1).
Among the non-CF control children, 40%, 59% and 36%,
respectively, had antibody titers below the limit of quantitation
and 24%, 29%, and 16% had antibody titers ≥ 100 against
alkaline protease, exotoxin A and elastase, respectively. Among
94 serum samples randomly selected from 94 age-matched CF
children, 33%, 31% and 53%, respectively, had antibody titers
below the limit of quantitation and 27%, 28%, and 21% had
antibody titers ≥ 100 against alkaline protease, exotoxin A and
elastase, respectively.
In logistic regression models, serum exotoxin A and elastase
antibody titers, but not alkaline protease antibody titers, were
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Fig. 1. Serum antibody titers in non-CF control children, children with CF that remained Pa negative for the subsequent year and children with CF that had initial
isolation of Pa from a respiratory culture within the subsequent year. Box plots of serum titers of antibodies against Pa alkaline protease (left panel), exotoxin A
(center panel), and elastase (right panel). Non-CF control children (hashed bars), children with CF that did not have Pa cultured in the subsequent year after serum
collection (clear bars), and children with CF that had Pa cultured within the subsequent 12 months, 6 months, and concurrently with serum collection (gray bars) are
shown. Sample sizes are shown above the bars. Medians, 25th and 75th percentiles and ranges are depicted.
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(P b .001), or Pa isolation within 6 months (P b .001) or
12 months (P ≤ .001) of serum collection among participants
with CF, with odds ratios generally b2 (Fig. 2). Of the three Pa
antigens, exotoxin A consistently had the largest effect size.
Odds ratios decreased as the interval of time between serum
collection and subsequent Pa isolation increased (Fig. 2).
ROC curve analyses and area under the curve (AUC)
calculations for children with CF confirmed the relatively low
diagnostic accuracy of antibody titers against all three antigens
for predicting Pa isolation from respiratory cultures, with the
highest AUC being 0.690 (a value of 0.5 indicates no association10.5 2 3
Elastase
Titer
Exotoxin A
Titer
Alkaline Protease
Titer
<1 year after<6 months afterconcurrent
Fig. 2. Odds ratios for the effect of log10 serum antibody titers on risk of
concurrent Pa isolation and Pa isolation within 6 months and 12 months after
serum collection in children with CF. A logistic regression model was adjusted
for patient sex and age (1–≤3 years, N3–≤6 years, N6 years). Odds ratios (log
scale) are shown for risk of concurrent Pa isolation (clear circles), Pa isolation
within 6 months after serum collection (gray circles), and within 12 months
(black circles) after serum collection. Bars represent 95% confidence intervals
for odds ratios.between the diagnostic test and the outcome). The rank order of
association between antibody titers and probability of subsequent
Pa isolation was exotoxin A N elastase N alkaline protease, and
the AUCs were highest for concurrent isolation of Pa (Fig. 3).
Based on the ROC curves in Fig. 3, antibody titer cutpoints
of ≥100 were used to test the accuracy of seropositivity
compared to concurrent and subsequent Pa isolation (Table 2).
In addition to studying each antigen independently, the
predictive ability of combinations of seropositivity for the
three antigens was analyzed. The ability of positive serology to
predict subsequent Pa isolation (positive predictive value,
PPV) was generally poor, ranging from 34.1% (95% CI 26.0,
43.3) to 61.1% (95% CI 43.5, 76.4). The greatest PPV was
achieved when all three antibody titers were positive, and the
PPV increased with the length of time allowed after serum
collection for detection of a positive culture. The latter finding
is at least in part due to the fact that predictive values are
influenced by prevalence (whereas sensitivity and specificity
are not). The prevalence of isolation of Pa within 6 months and
12 months of serum sample collection were 34% and 45%,
respectively. Among children with CF who had serum antibody
titers ≥ 100 for all three Pa antigens, 56.2% went on to have
Pa cultured within 6 months and 61.1% within a year.
The ability of negative serology to predict no subsequent
isolation of Pa (negative predictive value, NPV) was better than
the PPV, ranging from 54.4% (95%CI 49.6, 59.1) to 70.7% (95%
CI 65.6, 75.4). The NPV of exotoxin A antibody titers b 100 was
greater than that of other antibodies, either alone or in
combination with exotoxin A. The NPV for serology decreased
with increasing time from serum collection to culture, again, in
part due to fact the predictive values are influenced by
prevalence. For instance, only 70.7% of children with exotoxin
A antibody titers b100 remained Pa negative for up to 6 months,
and only 59.7% was Pa negative for up to a year after serum
collection (Table 2).
Fig. 3. ROC curves for serology as a predictor of subsequent Pa isolation in children with CF. Curves for alkaline protease (left), exotoxin A (center), and elastase
(right) prediction of concurrent Pa isolation (black lines), within 6 months (gray lines), and within 12 months (hashed lines) of serum collection are shown. Antibody
titers of 100 (open circles) are noted.
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Serum antibody titers were generally lower in children with
CF less than 6 years of age than in older children (Fig. 4—online
supplement). Thus, we constructed ROC curves CF by age group
(1 to b6 and ≥6 years old) (Fig. 4—online supplement). Using
these data, optimal antibody titer cutpoints for each age group
were determined using serum sample level modeling (Table 3—
online supplement). Age-specific titer cutpoints improved the
diagnostic properties of serologic assays for prediction of Pa
isolation (Table 4—online supplement). For example, the best
PPV for Pa isolation in the subsequent 6 months when titers for
all three antibodies were ≥100 improved from 56.2% (CI 37.9,
73.2) (Table 2) to 76.2% (CI 52.5, 90.9) using age-specific
cutpoints (Table 4—online supplement). Cutpoints optimized byTable 2
Seropositivity (titers ≥ 100) as a predictor of concurrent or subsequent Pa isolation
Individual Pa antigens with an
Alkaline
protease
Exotoxin A
Pa isolation concurrent with serum collection
Sensitivity a 35.3 (24.4, 47.9) 54.4 (41.9, 6
Specificity b 75.0 (69.8, 79.6) 75.9 (70.8, 8
Positive predictive value c 23.3 (15.8, 32.9) 32.7 (24.4, 4
Negative predictive value d 84.3 (79.4, 88.3) 88.6 (84.0, 9
Pa isolation within 6 months after serum collection
Sensitivity 24.9 (18.7, 32.2) 39.1 (31.7, 4
Specificity 74.8 (69.6, 79.4) 77.6 (72.5, 8
Positive predictive value 34.1 (26.0, 43.3) 47.8 (39.3, 5
Negative predictive value 65.4 (60.3, 70.2) 70.7 (65.6, 7
Pa isolation within 12 months after serum collection
Sensitivity 23.0 (18.1, 28.7) 35.6 (29.9, 4
Specificity 74.8 (69.6, 79.4) 77.6 (72.5, 8
Positive predictive value 42.6 (34.4, 51.2) 56.4 (48.4, 6
Negative predictive value 54.4 (49.6, 59.1) 59.7 (54.8, 6
a Proportion of patients with antibody titers ≥ 100 among those who had subsequ
b Proportion of patients with antibody titers b 100 among those who remained cu
c Proportion of patients who had subsequent Pa isolation among those with antib
d Proportion of patients who remained culture negative among those with antibodage produced a much smaller improvement in the NPV for Pa
isolation in the subsequent 6 months, going from 67.8% (CI 61.8,
73.3) to 72.1% (CI 66.5, 77.1) for presence of≥1 antibody above
the cutpoint (Table 2 and online supplement Table 4). The
highest positive and negative predictive values for concurrent Pa
isolation and isolation in the subsequent 6 or 12 months using
both sets of antibody titer cutpoints are shown in Fig. 5 (online
supplement).
4. Discussion
Based on reports by our group [2] and others [31] that positive
serology may precede first isolation of Pa from respiratory
cultures, we aimed to assess whetherPa serology could accurately
predict subsequent isolation of Pa from oropharyngeal cultures inamong children with CF.
tibody titers ≥ 100 Number of Pa antigens with antibody titers ≥ 100
Elastase ≥1/3 ≥2/3 3/3
6.4) 32.4 (21.8, 44.9) 66.2 (53.6, 76.9) 41.2 (29.6, 53.8) 14.7 (7.7, 25.8)
0.5) 84.2 (79.6, 87.9) 55.7 (50.0, 61.2) 83.9 (79.2, 87.6) 95.6 (92.5, 97.5)
2.3) 30.6 (20.5, 42.7) 24.3 (18.5, 31.3) 35.4 (25.2, 47.1) 41.7 (22.8, 63.1)
2.0) 85.3 (80.7, 88.9) 88.4 (83.0, 92.4) 86.9 (82.5, 90.4) 83.9 (79.6, 87.4)
6.9) 23.7 (17.6, 30.9) 49.7 (42.0, 57.5) 27.2 (20.8, 34.7) 10.7 (6.6, 16.5)
1.9) 84.1 (79.5, 87.8) 55.8 (50.1, 61.2) 85.0 (80.6, 88.7) 95.6 (92.6, 97.5)
6.5) 44.0 (33.7, 54.7) 37.2 (30.9, 43.9) 48.9 (38.6, 59.4) 56.2 (37.9, 73.2)
5.4) 67.7 (62.8, 72.2) 67.8 (61.8, 73.3) 68.9 (64.1, 73.4) 67.0 (62.5, 71.3)
1.8) 19.2 (14.7, 24.6) 45.6 (39.5, 51.8) 23.8 (18.8, 29.5) 8.4 (5.5, 12.7)
1.9) 84.1 (79.5, 87.8) 55.8 (50.1, 61.2) 85.0 (80.6, 88.7) 95.6 (92.6, 97.5)
4.0) 49.5 (39.5, 59.6) 45.6 (39.5, 51.8) 56.4 (46.6, 65.7) 61.1 (43.5, 76.4)
0.6) 56.1 (51.6, 60.6) 55.8 (50.1, 61.2) 57.8 (53.2, 62.3) 56.2 (51.9, 60.4)
ent Pa isolation with confidence intervals.
lture negative with confidence intervals.
ody titers ≥ 100 with confidence intervals.
y titers b100 with confidence intervals.
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serology might potentially allow for earlier detection of Pa
infection and therefore earlier initiation of Pa eradication therapy,
potentially improving outcomes. Unfortunately, we found that
positive serologywas not able to accurately predict isolation of Pa
in the ensuing 6 or 12 months. In our cohort, even using antibody
titer cutpoints optimized for age, the positive predictive value of
Pa serology for predicting isolation of Pa from a respiratory
culture in the ensuing 6 months was 76.2% and the negative
predictive value was 72.1%. In other words, about 1 in 4 children
predicted based on positive serology to become Pa positive in the
next 6 months did not actually acquire Pa during that time period,
while 1 in 4 children predicted by negative serology to remain Pa
negative in the next 6 months in fact became Pa positive during
the same period.
Isolation of new Pa from oropharyngeal cultures in children
with CF is not a clinical endpoint, but rather an admittedly
imperfect diagnostic test [4], and it seems clear that some of the
inability of serology to predict subsequent Pa isolation in our
study is a result of the limitations of our chosen “gold standard”
rather than of Pa serology. Molecular methods for detection of
Pa infection are gaining traction [24–27,31] and had we utilized
such techniques, our outcomes may have been different.
However, because treatment decisions in the U.S. are still
generally made today based on Pa isolation from conventional
upper airway cultures [18], we felt it was reasonable to test the
ability of serology to act as a diagnostic surrogate for Pa isolation
from these cultures. The presence of substantial titers of
antibodies to Pa in children without CF (Fig. 1) and the relatively
poor predictive power of optimized serology in children with CF
(Fig. 5—online supplement) suggest that serology as we have
studied it would not be a particularly useful diagnostic surrogate
for upper airway culture. In addition, Douglas et al. [17] found
very similar results to ours when comparing Pa serology to
simultaneous lower airway cultures obtained by BAL.Whether or
not intervening with anti-pseudomonal antibiotics when positive
serology is first detected might improve outcomes is an entirely
different question from the one we evaluated, one requiring a
randomized, controlled trial in which clinical endpoints rather
than surrogate outcomes such as oropharyngeal cultures are
evaluated.
Though ours is the first study to evaluate the utility of Pa
serology in predicting subsequent first isolation of Pa from
respiratory cultures among Pa negative patients, several prospec-
tive studies have evaluated the diagnostic utility of serology
compared to concurrent respiratory cultures in early Pa infection,
with conflicting results. Douglas et al. [17], reported similarly low
positive and negative predictive values of serology in young CF
patients undergoing BAL. Others have reported higher diagnostic
accuracy [29,30,38]. These differences can be attributed to the
specific antigens evaluated, the choice of cutpoint for defining a
positive titer, the prevalence ofPa in the population tested, and the
source of respiratory cultures (sputum vs. oropharyngeal swabs
vs. BAL) [25].
In the early development of ELISA assays for Pa antibodies,
several investigators looked for serum Pa antibodies in non-CF
children with no history of Pa infection [23,39–41]. To ourknowledge, ours is the first study to evaluate Pa serology in
non-CF control children in whom concurrent OP cultures were
performed. Among the 94 control children in our study, in whom
Pa was isolated from an OP culture in only one, there was
nonetheless evidence of possible prior Pa infection based on
Pa serologic titers N100. Interestingly, van Ewijk et al. [42]
performed serial OP cultures in 20 children with CF and 19
unrelated healthy controls each time the children presented with
signs and symptoms of a viral respiratory infection during one
viral season, and isolated Pa from 37% of the controls and 30%
of the children with CF. The Pa persisted in the children with CF
whereas it was rapidly cleared from the control children. Thus,
the respiratory tract may be a common site of Pa infection in
healthy children. Other potential sources of mucosal invasion
could include the skin, gastrointestinal or genitourinary tracts.
Whether or not these healthy children truly had experienced Pa
infection, the lack of specificity of Pa antibodies to children with
CF is one reason why Pa serology may be less useful in detecting
early Pa infection in children with CF.
Our study has several limitations in addition to sampling
oropharyngeal swabs rather than BAL for assessment of
respiratory cultures. First, serum for serology was only collected
annually, so conclusions regarding more frequent sampling
cannot be drawn. However, routine annual blood tests are
standard of care in the U.S. Secondly, since positive and negative
predictive values are affected by prevalence, the observation that
PPV increases while NPV decreases with increased observation
time after serum collection is in part due to the increased
prevalence of Pa-positivity with increasing observation time.
Similarly, our results should not be generalized to populations
with widely different rates of Pa acquisition. Finally, we did not
evaluate the effect of Pa eradication treatment on Pa serology,
though Ratjen et al. [30] and Anstead et al. [37], have both
demonstrated that Pa antibody titers may be useful in monitoring
response to treatment. Finally, we chose to evaluate Pa serology
using a commercial assay so that it could easily be adopted by
clinical laboratories. We measured IgG antibodies to elastase,
alkaline phosphatase and exotoxin A, as these antibodies have
been extensively evaluated in CF [17,22,24,25,27–31,37]. Our
results should not be generalized to serologic assays for
antibodies to other antigens, other antibodies (i.e. IgM, IgA) to
these antigens, or non-commercial kits for the antibodies we
studied [43]. It is possible that serology to other antigens, such as
flagellar antigens, might have yielded different results [44,45].
In conclusion, our results demonstrate that Pa serology is
only modestly accurate in predicting subsequent first isolation
of Pa from upper respiratory cultures among Pa negative CF
patients. Thus, the role of Pa serology in the routine monitoring
of early Pa infection remains unclear.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.06.005.
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